ACOG

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

Retrieved on: 
Freitag, Mai 17, 2024
Technology policy, Episcopal conference, Booth, ACOG, FDA, Cervical cancer, Collection, Uterine cancer, Cancer Moonshot, Woman, Policy, American College, OSTP, Cancer, Birth control

According to The White House , OSTP “works to bring that idea to life by harnessing the power of science, technology, and innovation to achieve America’s great aspirations.” OSTP also supports the Cancer Moonshot, which is focused on mobilizing a national effort to end cancer.

Key Points: 
  • According to The White House , OSTP “works to bring that idea to life by harnessing the power of science, technology, and innovation to achieve America’s great aspirations.” OSTP also supports the Cancer Moonshot, which is focused on mobilizing a national effort to end cancer.
  • During the meeting, Ms. Lee-Sepsick and the OSTP staff discussed the priority actions for the Cancer Moonshot, including  important priorities related to cervical cancer.
  • Femasys intends to broaden its cancer diagnostic portfolio with an endometrial sampler for uterine cancer in the future.
  • The event is taking place in San Francisco’s Moscone Center May 17-19, 2024 and Femasys will be exhibiting at Booth #1413.

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council

Retrieved on: 
Donnerstag, Mai 16, 2024
OMB, Episcopal conference, Booth, Initiative, The, ACOG, Education, FDA, Government, Health, GPC, Assistant, Research, Woman, Policy, Infertility, American College, Innovation

ATLANTA, May 16, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces CEO and Founder Kathy Lee-Sepsick met with the White House’s Gender Policy Council (GPC) staff to discuss the Company’s reproductive health products and the future of women’s health in the United States.

Key Points: 
  • ATLANTA, May 16, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces CEO and Founder Kathy Lee-Sepsick met with the White House’s Gender Policy Council (GPC) staff to discuss the Company’s reproductive health products and the future of women’s health in the United States.
  • According to The White House , “The GPC covers a range of issues including economic security, health, gender-based violence and education, with a focus on gender equity and equality, and particular attention to the barriers faced by women and girls.”
    As part of the discussion, Ms. Lee-Sepsick and the GPC staff discussed the crucial need to fund women’s healthcare initiatives.
  • “Given the mutual acknowledgement of the pressing need to fund late-stage women’s health innovations, as well as the gaps in research to address multiple women’s health issues, we believe Femasys can serve to provide historical perspective of the challenges of advancing a company in women’s health and can be instrumental in realizing the mission of closing gender disparities in critical areas.
  • The event is taking place in San Francisco’s Moscone Center May 17-19, 2024 and Femasys will be exhibiting at Booth #1413.

Elinzanetant significantly reduces frequency and severity of moderate to severe hot flashes associated with menopause

Retrieved on: 
Donnerstag, Mai 16, 2024
Biotechnology, Other Health, Health, General Health, Women, Pharmaceutical, Other Science, Research, Consumer, Science, Clinical Trials, American College, Hot, Elinzanetant, Menopause, VMS, Sleep, Quality of life, ACOG

Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, showing that the investigational compound elinzanetant significantly reduced frequency and severity of moderate to severe vasomotor symptoms (VMS; also known as hot flashes) associated with menopause compared to placebo.

Key Points: 
  • Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, showing that the investigational compound elinzanetant significantly reduced frequency and severity of moderate to severe vasomotor symptoms (VMS; also known as hot flashes) associated with menopause compared to placebo.
  • Elinzanetant successfully met all four primary endpoints in both studies demonstrating statistically significant reductions in the frequency and severity of moderate to severe VMS from baseline to week 4 and 12 compared to placebo.
  • In this study, elinzanetant successfully met the primary endpoint demonstrating a statistically significant reduction in the frequency of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) from baseline to week 12 compared to placebo.
  • Bayer will submit the data from the OASIS 1, 2 and 3 studies to health authorities for approval of marketing authorizations of elinzanetant for the treatment of moderate to severe VMS associated with menopause.

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Retrieved on: 
Dienstag, Mai 7, 2024
FDA, Episcopal conference, American College, Woman, Infertility, Insemination, Health, ICSI, IVF, ACOG, Booth, IUI

With the addition of new team members to its commercial team in key strategic geographical locations, Femasys is poised to fully initiate its strategic initiatives and execute on its delivery of innovative, accessible options to impact women’s healthcare.

Key Points: 
  • With the addition of new team members to its commercial team in key strategic geographical locations, Femasys is poised to fully initiate its strategic initiatives and execute on its delivery of innovative, accessible options to impact women’s healthcare.
  • The newly appointed team brings together seasoned professionals with a wealth of commercial experience across various sectors of the healthcare industry.
  • Their collective expertise plays a pivotal role in driving Femasys' commercial efforts forward to realize the Company’s strategic vision, with initial emphasis on the Company’s infertility portfolio, led by the FemaSeed® product.
  • The 2024 ACOG meeting presents an ideal opportunity for Femasys to showcase the strength of its initial commercial team and its commitment to shaping the future of women's healthcare.

Bayer to unveil late-breaking data from Phase III OASIS 1 and 2 for elinzanetant in the treatment of vasomotor symptoms associated with menopause

Retrieved on: 
Mittwoch, Mai 8, 2024
Science, Women, Research, Pharmaceutical, Health, Baby, Maternity, Consumer, Clinical Trials, Episcopal conference, American College, Safety, Woman, ACOG, Endometrial hyperplasia, Treatment, Systematic review, Meta-analysis, IUS

Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo, at the upcoming American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting.

Key Points: 
  • Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo, at the upcoming American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting.
  • ACOG takes place from May 17 – 19, in San Francisco, CA, United States.
  • Additional presentations will feature new findings from Bayer’s intrauterine systems (IUS) and menopause product portfolio, as well as a scientific symposium session on the science behind menopause symptoms.
  • These presentations demonstrate Bayer’s long-standing commitment to advance women’s healthcare as the company works towards broadening treatment options for women.

Grady Receives Highest Maternal Care Verification from The Joint Commission

Retrieved on: 
Mittwoch, Mai 1, 2024
Consensus, Mortality, DNP, American College, Level, Verification, Woman, Joint Commission, ACOG, Certification, RN, MLC, Disease, Mother, MBA, OCC, Nursing

ATLANTA, May 1, 2024 /PRNewswire/ -- The Joint Commission's Maternal Levels of Care (MLC) Verification program, offered in collaboration with the American College of Obstetricians and Gynecologists (ACOG), has named Grady Health System as a Level IV maternal care verified facility.

Key Points: 
  • ATLANTA, May 1, 2024 /PRNewswire/ -- The Joint Commission's Maternal Levels of Care (MLC) Verification program, offered in collaboration with the American College of Obstetricians and Gynecologists (ACOG), has named Grady Health System as a Level IV maternal care verified facility.
  • As a Level IV facility, the highest designation, Grady demonstrated its on-site medical and surgical care for the most complex maternal conditions and critically ill pregnant women and fetuses throughout antepartum, intrapartum, and postpartum care.
  • "The Joint Commission commends Grady Health System for being named a Level IV maternal care verified facility and for its efforts to standardize maternal care and reduce maternal morbidity and mortality," says Ken Grubbs, DNP, MBA, RN, executive vice president of Accreditation and Certification Operations and chief nursing officer, The Joint Commission.
  • "The Maternal Levels of Care Verification program will help Grady strengthen regionalized care for mothers and babies in its community."

Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage

Retrieved on: 
Mittwoch, Mai 1, 2024
Health, Consumer, Women, Genetics, Baby, Maternity, Clinical Trials, Biotechnology, Fetus, Nucleic acid thermodynamics, Gamma globulin, Episcopal conference, American College, NTRA, Laboratory, RHD (gene), Anemia, Risk, Pregnancy, Blood, Northwell Health, Quality, Genetic testing, Obstetrics, DNA, SNP, ACOG, ASHG, NIPT, Patient, Human genetics, Society, Physician, Antibody, Panorama, Dietary supplement

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test.
  • This comes at a critical time for the healthcare industry, helping physicians navigate patient care given nationwide shortages of Rho(D) immune globulin therapy (RhIg).
  • Natera’s test can be performed as early as nine weeks gestation and determines fetal RhD status from the blood of a pregnant patient, including complex pseudogene and RhD-CE-D hybrid variants.
  • The vast majority of other NIPT laboratories do not offer fetal RhD assessment, which makes it a key differentiator in addition to Natera’s core SNP-based technology.

Curio Digital Therapeutics Inc. Announces the U.S. Food and Drug Administration (FDA) Clearance of MamaLift Plus™, the First Prescription Digital Therapeutic Authorized for the Treatment of Postpartum Depression (PPD)

Retrieved on: 
Dienstag, April 23, 2024
Mental Health, Women, FDA, Baby, Maternity, Clinical Trials, Biotechnology, Health, Consumer, Pharmaceutical, American College, Regulation, PPD, Woman, Behavioral activation, Food, Cognitive behavioral therapy, BAT, Depression, DBT, Smartphone, Summer, ACOG, Therapy, Edinburgh Postnatal Depression Scale, Patient, MPH, Postpartum depression, Face, ITT, IPT, RCT, Dialectical behavior therapy, CBT, EPDS

Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM.

Key Points: 
  • Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM.
  • MamaLift Plus treats mild to moderate postpartum depression by improving a patient’s symptoms of depression.
  • MamaLift Plus delivers digital Cognitive Behavioral Therapy (CBT), Behavioral Activation Therapy (BAT), Interpersonal Therapy (IPT), and Dialectical Behavior Therapy (DBT) for postpartum depression.
  • The clearance of MamaLift Plus is based on results from the Supporting Maternal Mental Health and Emotional Regulation (SuMMER).

The Inner Circle acknowledges Jaleen D. Sims, MD, MPH, FACOG as a Pinnacle Lifetime Member

Retrieved on: 
Freitag, März 22, 2024
Well, Health, Organization, Birth, Gynaecology, Motivation, Public health, HOPE, Mentorship, Trust, FACOG, Patient, Knowledge, MSMA, University, MMSA, Woman, Wichita State University, American College, MPH, ACOG, Multimedia, Family, Physician, Inner circle, Medicine, Nursing

FLOWOOD, Miss., March 22, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Jaleen D. Sims, MD, MPH, FACOG is acknowledged as a Pinnacle Lifetime Member for her contributions as a Leading Obstetrics and Gynecology Specialist.

Key Points: 
  • FLOWOOD, Miss., March 22, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Jaleen D. Sims, MD, MPH, FACOG is acknowledged as a Pinnacle Lifetime Member for her contributions as a Leading Obstetrics and Gynecology Specialist.
  • Dr. Jaleen D. Sims, MD, MPH, FACOG, practicing board certified OB/GYN at Jackson-Hinds Comprehensive Health Center in Jackson, MS, is a leading figure in women's healthcare.
  • She is making waves in Mississippi with her expertise in normal and high-risk pregnancies, minimally invasive gynecological procedures, teen gynecology, contraception, and preventative cancer screenings.
  • Her dedication to advancing women's healthcare has earned her the trust and admiration of both patients and peers.

BayCare's St. Joseph's Women's Hospital Achieves Level IV Maternal Care Certification from The Joint Commission

Retrieved on: 
Donnerstag, März 21, 2024
Consensus, Mother, RN, Disease, Certification, Culture, Cone Health Women's Hospital, Level, Central Florida, Woman, Joint Commission, MLC, Mental, Partnership, Education, Verification, DNP, Patient, Mental health, Mortality, Anesthesiology, University, MBA, American College, OCC, Hospital, ACOG, Health, Nursing

TAMPA, Fla., March 21, 2024 /PRNewswire/ -- BayCare, the leading health care system in West Central Florida, today announced that St. Joseph's Women's Hospital has attained the highest level of certification in Maternal Care by The Joint Commission, the nation's oldest health care accrediting organization.

Key Points: 
  • TAMPA, Fla., March 21, 2024 /PRNewswire/ -- BayCare, the leading health care system in West Central Florida, today announced that St. Joseph's Women's Hospital has attained the highest level of certification in Maternal Care by The Joint Commission, the nation's oldest health care accrediting organization.
  • As a Level IV maternal care verified facility, St. Joseph's Women's Hospital is recognized for its commitment to providing exceptional maternal healthcare services.
  • "The Joint Commission commends St. Joseph's Women's Hospital for being named a Level IV maternal care verified facility and for its efforts to standardize maternal care and reduce maternal morbidity and mortality," says Ken Grubbs, DNP, MBA, RN, executive vice president of Accreditation and Certification Operations and chief nursing officer, The Joint Commission.
  • "The Maternal Levels of Care Verification program will help St. Joseph's Women's Hospital strengthen regionalized care for mothers and babies in its community."